BioSpace News Archive

Avalo Therapeutics, Inc. today announced the appointment of Dr. June Almenoff, effective November 10, 2021, and Mitchell Chan, effective December 1, 2021 as independent members of its Board.

Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based pharmaceuticals is pleased to announce that it has filed a provisional patent application in the United States Patent and Trademark Office for a novel oral cannabinoid technology (the “Formulation Candidates”).

ECMOHO Limited today announced a change in its board of directors (the “Board”).

Inflammasome Therapeutics (https://inflam.com), said today that research published in Science Immunology (https://www.science.org/doi/10.1126/sciimmunol.abi4493) “DDX17 is an essential mediator of sterile NLRC4 inflammasome activation by retrotransposon RNAs”, uncovers a previously unrecognized mechanism by which NLRC4 combines with NLRP3 to form activated inflammasomes that trigger causes of active disease in macular degeneration and lupus.

Applied Genetic Technologies Corporation today announced the appointment of James Robinson, President and Chief Executive Officer (CEO).

TFF Pharmaceuticals, Inc. today announced that it will host a science day related to two of the company’s lead assets, inhaled voriconazole for invasive pulmonary aspergillosis (IPA) and inhaled AUG-3387 for COVID-19, on Monday, December 13, 2021.

Kymera Therapeutics, Inc. today announced the appointment of Vijay Sabesan as Senior Vice President, Technical Operations.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application (number 16/194,417) covering AllocetraTM, the Company’s immunotherapy product candidate.

Carisma Therapeutics announced today that it has entered into a clinical study collaboration with Merck (known as MSD outside the US and Canada ) to evaluate their proprietary targeted chimeric antigen receptor macrophages (CAR-M) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing cancers.

Goldfinch Bio today announced the appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer (CSO).